Cargando…

The human immunodeficiency virus protease inhibitor ritonavir is potentially active against urological malignancies

The human immunodeficiency virus protease inhibitor ritonavir has recently been shown to have antineoplastic activity, and its use in urological malignancies is under investigation with an eye toward drug repositioning. Ritonavir is thought to exert its antineoplastic activity by inhibiting multiple...

Descripción completa

Detalles Bibliográficos
Autor principal:	Sato, Akinori
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2015
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4399512/ https://www.ncbi.nlm.nih.gov/pubmed/25914545 http://dx.doi.org/10.2147/OTT.S79776

Ejemplares similares

Sildenafil and Bosentan Plasma Concentrations in a Human Immunodeficiency Virus- Infected Patient with Pulmonary Arterial Hypertension Treated with Ritonavir-Boosted Protease Inhibitor
por: Chinello, Pierangelo, et al.
Publicado: (2015)

Interactions of the protease inhibitor, ritonavir, with common anesthesia drugs
por: Svedmyr, Anders, et al.
Publicado: (2022)

Safety and Tolerability of High Dose Atazanavir–Ritonavir and Lopinavir–Ritonavir in Pregnant Women Living with Human Immunodeficiency Virus
por: McLaughlin, Milena M, et al.
Publicado: (2017)

Cardio-Metabolic Effects of HIV Protease Inhibitors (Lopinavir/Ritonavir)
por: Reyskens, Kathleen M. S. E., et al.
Publicado: (2013)

Metabolic abnormalities in human immunodeficiency virus patients with protease inhibitor-based therapy
por: Ete, Tumnyak, et al.
Publicado: (2014)

Correction: Cardio-Metabolic Effects of HIV Protease Inhibitors (Lopinavir/Ritonavir)
por: Reyskens, Kathleen M. S. E., et al.
Publicado: (2013)

Is Ritonavir-Boosted Atazanavir a Risk for Cholelithiasis Compared to Other Protease Inhibitors?
por: Hamada, Yohei, et al.
Publicado: (2013)

Evolution of gag and gp41 in Patients Receiving Ritonavir-Boosted Protease Inhibitors
por: Manasa, Justen, et al.
Publicado: (2017)

Management of Antiretroviral Therapy with Boosted Protease Inhibitors—Darunavir/Ritonavir or Darunavir/Cobicistat
por: Marin, Ruxandra-Cristina, et al.
Publicado: (2021)

Checkpoint inhibitors in the treatment of urological malignancies
por: Popovic, Lazar S, et al.
Publicado: (2017)

Human Immunodeficiency Virus gag and protease: partners in resistance
por: Fun, Axel, et al.
Publicado: (2012)

Effectiveness of Ritonavir-Boosted Protease Inhibitor Monotherapy in Clinical Practice Even with Previous Virological Failures to Protease Inhibitor-Based Regimens
por: López-Cortés, Luis F., et al.
Publicado: (2016)

Enzymatic activity of human immunodeficiency virus type 1 protease in crowded solutions
por: Maximova, Ksenia, et al.
Publicado: (2019)

HIV-1 subtype influences susceptibility and response to monotherapy with the protease inhibitor lopinavir/ritonavir
por: Sutherland, K. A., et al.
Publicado: (2015)

Co-administration of ritonavir-boosted protease inhibitors and rate of tenofovir discontinuation in clinical practice
por: Costarelli, Silvia, et al.
Publicado: (2014)

Treatment Switch to Dolutegravir With 2 Nucleoside Reverse-Transcriptase Inhibitors (NRTI) in Comparison to Continuation With Protease Inhibitor/Ritonavir Among Patients With Human Immunodeficiency Virus at Risk for Prior NRTI Resistance: A Cohort Analysis of Real-World Data
por: Sangaré, Mohamed N’dongo, et al.
Publicado: (2020)

Farnesyltransferase inhibitors prevent HIV protease inhibitor (lopinavir/ritonavir)-induced lipodystrophy and metabolic syndrome in mice
por: Tanaka, Tomokazu, et al.
Publicado: (2018)

Two Cases of Multidrug-Resistant Human Immunodeficiency Virus Infection Treated with Atazanavir and Lopinavir/Ritonavir Combination Therapy
por: Choi, Heekyoung, et al.
Publicado: (2008)

The Bile Acid Sensor FXR Protects against Dyslipidemia and Aortic Plaques Development Induced by the HIV Protease Inhibitor Ritonavir in Mice
por: Mencarelli, Andrea, et al.
Publicado: (2010)

Estimation and Comparison of Salivary Secretory Leukocyte Protease Inhibitor in Human Immunodeficiency Virus Patients and Healthy Individuals
por: Pushpanshu, Kumar, et al.
Publicado: (2014)

Resistance mechanism of human immunodeficiency virus type-1 protease to inhibitors: A molecular dynamic approach
por: Dayer, Mohammad Reza, et al.
Publicado: (2014)

Ritonavir-Boosted Protease Inhibitors Do Not Significantly Affect the Performance of Creatinine-Based Estimates of GFR
por: Wyatt, Christina M., et al.
Publicado: (2020)

Phase 3 trial of first generation protease inhibitor therapy for hepatitis C virus/human immunodeficiency virus coinfection
por: Sherman, Kenneth E, et al.
Publicado: (2017)

Validation of Simultaneous Quantitative Method of HIV Protease Inhibitors Atazanavir, Darunavir and Ritonavir in Human Plasma by UPLC-MS/MS
por: Mishra, Tulsidas, et al.
Publicado: (2014)

Selective killing of human immunodeficiency virus infected cells by non-nucleoside reverse transcriptase inhibitor-induced activation of HIV protease
por: Jochmans, Dirk, et al.
Publicado: (2010)

Simultaneous assay for protease activities of hepatitis C virus and human immunodeficiency virus based on fluorescence detection
por: Kabashima, Tsutomu, et al.
Publicado: (2019)

Malignant syphilis with human immunodeficiency virus infection
por: Rajan, Jiby, et al.
Publicado: (2011)

Long term effect of switching to darunavir/ritonavir in HIV infected patients previously on protease inhibitor therapy
por: Ucciferri, Claudio, et al.
Publicado: (2016)

Pharmacokinetics of Oral Nirmatrelvir/Ritonavir, a Protease Inhibitor for Treatment of COVID‐19, in Subjects With Renal Impairment
por: Toussi, Sima S., et al.
Publicado: (2022)

Selective and facile assay of human immunodeficiency virus protease activity by a novel fluorogenic reaction
por: Yu, Zhiqiang, et al.
Publicado: (2010)

Drug-drug interactions of ritonavir-boosted SARS-CoV-2 protease inhibitors in solid organ transplant recipients: experience from the initial use of lopinavir-ritonavir
por: Gonzalez-García, Ruben, et al.
Publicado: (2023)

Urologic Problems in Patients with Acquired Immunodeficiency Syndrome
por: Staiman, Victoria R., et al.
Publicado: (2004)

Efficacy and safety of a dual boosted protease inhibitor-based regimen, atazanavir and fosamprenavir/ritonavir, against HIV: experience in a pediatric population
por: Rusconi, Stefano, et al.
Publicado: (2012)

Context-dependent autoprocessing of human immunodeficiency virus type 1 protease precursors
por: Tien, ChihFeng, et al.
Publicado: (2018)

Detrimental clinical interaction between ritonavir-boosted protease inhibitors and vinblastin in HIV-infected patients with Hodgkin lymphoma
por: Cingolani, A, et al.
Publicado: (2010)

Switching from ritonavir to cobicistat in HIV patients with renal impairment who are virologically suppressed on a protease inhibitor
por: Fisher, Martin, et al.
Publicado: (2014)

Ombitasvir/paritaprevir/ritonavir & dasabuvir ± ribavirin following protease inhibitors failure - a prospective multi-centre trial
por: Deutsch, Liat, et al.
Publicado: (2020)

Chemotherapy and Urological Malignancy
por: Read, G.
Publicado: (1983)

Glyoxalases in Urological Malignancies
por: Antognelli, Cinzia, et al.
Publicado: (2018)

Potential pharmacokinetic interactions with concurrent use of herbal medicines and a ritonavir-boosted COVID-19 protease inhibitor in low and middle-income countries
por: Smith, Dallas J., et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_51llm2caf78h492dkg81itd03j